Corcept rises after ovarian cancer drug shows positive results in mid-stage study
CORT•Corcept Therapeutics said Lifyorli combined with chemotherapy drugs showed positive results in a 95-patient study, with median progression-free survival of 7.2 months and an objective response rate of 59%.
1. Study results
Corcept Therapeutics said its ovarian cancer drug Lifyorli, combined with nab-paclitaxel and bevacizumab, showed positive results in patients with platinum-resistant ovarian cancer. In the 95-patient study, median progression-free survival was 7.2 months and the objective response rate was 59%; among patients who had not previously received bevacizumab, the figures were 8.1 months and 66%.
